Matches in Nanopublications for { ?s ?p "DDI between Sulfadiazine and Tolbutamide - Tolbutamide and Sulfadiazine are strong CYP2C9 inhibitors and substrates. Decreased metabolism and clearance of both agents may occur during concomitant therapy. Consider alternate therpy or monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or dose(s) changed. [drugbank_resource:DB00359_DB01124]"@en ?g. }
Showing items 1 to 1 of
1
with 100 items per page.
- drugbank_resource:DB00359_DB01124 label "DDI between Sulfadiazine and Tolbutamide - Tolbutamide and Sulfadiazine are strong CYP2C9 inhibitors and substrates. Decreased metabolism and clearance of both agents may occur during concomitant therapy. Consider alternate therpy or monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or dose(s) changed. [drugbank_resource:DB00359_DB01124]" assertion.